.png){kind=icon}
.png){kind=icon}
Return
Beyond α-GalCer: Medicinal Chemistry Insights Driving Structural Evolution of CD1d Ligands
.png){kind=icon}
OA
AI
E
Ž
DOI：10.1021/acs.jmedchem.6c00783.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
CD1d-restricted glycolipids have emerged as a cornerstone in the development of next-generation immunotherapies. This perspective provides a comprehensive update on structure–activity relationships, specifically examining how modifications of the prototypical CD1d ligand α-galactosylceramide (α-GalCer) to the galactosyl headgroup, phytosphingosine base, and fatty acyl chain dictate the modulation of invariant natural killer T (iNKT) cell responses. We explore the key pharmacophores and receptor interactions that polarize subsequent immune response toward either a pro-inflammatory Th1 or an anti-inflammatory Th2 phenotype. Building upon the structural evolution of sophisticated chemotypes, we evaluate the potential of these agonists in synergistic combinations with other adjuvants. Furthermore, we highlight the emerging transition toward fully synthetic self-adjuvanting vaccines, which ensure cellular colocalization and coordinated activation by covalently integrating antigens with glycolipid agonists. Collectively, these advancements underscore the transformative potential of tailored glycolipid design in engineering specific and durable immunity against cancer and infectious diseases.
Keywords:
Cancer
Ligands
Lipids
Peptides and proteins
Vaccination
Journal
IF:
6.8
Papers:
2.7W
Citations:
9.4W
Organization
Cited Papers